Results 41 to 50 of about 87,574 (284)

Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]

, 2019
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus, Ren, Lei, Zhang, Luo, Zhang, Nan   +3 more
core   +1 more source

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. [PDF]

Muscle Nerve, 2021
AbstractImmunoglobulin G (IgG) therapy is an established long‐term treatment in chronic inflammatory demyelinating polyneuropathy (CIDP) that is commonly administered intravenously (IVIg). The subcutaneous immunoglobulin (SCIg) administration route is a safe and effective alternative option, approved by the United States Food and Drug Administration ...
Goyal NA, Karam C, Sheikh KA, Dimachkie MM.   +3 more
europepmc   +6 more sources

Immunoglobulin replacement treatment by rapid subcutaneous infusion [PDF]

Archives of Disease in Childhood, 1998
Long term intravenous immunoglobulin (IVIG) infusion is an effective treatment for children with immunodeficiencies, but can be complicated by poor venous access, systemic adverse reactions, and the need for frequent hospital admission. Rapid subcutaneous immunoglobulin (SCIG) infusion has been found to be effective in adults with primary ...
J, Gaspar, B, Gerritsen, A, Jones
openaire   +2 more sources

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy

Scientific Reports, 2021
Multifocal motor neuropathy (MMN) is a rare disease with a prevalence of less than 1 per 100,000 people. Intravenous immunoglobulin (IVIG) therapy, performed for a long-term period, has been demonstrated able to improve the clinical picture of MMN ...
Luca Gentile, Massimo Russo, Carmelo Rodolico, Ilenia Arimatea, Giuseppe Vita, Antonio Toscano, Anna Mazzeo   +6 more
doaj   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Facilitated subcutaneous immunoglobulin (fSCIg) therapy – practical considerations [PDF]

Clinical and Experimental Immunology, 2015
Summary There is an increasing range of therapeutic options for primary antibody-deficient patients who require replacement immunoglobulin. These include intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), rapid push SCIg and most recently recombinant human hyaluronidase-facilitated SCIg (fSCIg).
M, Ponsford, E, Carne, C, Kingdon, C, Joyce, C, Price, C, Williams, T, El-Shanawany, P, Williams, S, Jolles   +8 more
openaire   +2 more sources

The New Formulations of Immunoglobulin Replacement Therapies and Future Aspects

Turkish Journal of Immunology
Immunoglobulin replacement therapy (IgRT) stands as the established method of treatment for numerous inborn errors of immunity (IEI). Over the past six decades, there have been notable advancements in the dosing, processing, and administration routes of ...
Elif Karakoç-aydıner
doaj   +1 more source

Anti-Inflammatory and Immunomodulatory Effect of High-Dose Immunoglobulins in Children: From Approved Indications to Off-Label Use

Cells, 2023
Background: The large-scale utilization of immunoglobulins in patients with inborn errors of immunity (IEIs) since 1952 prompted the discovery of their key role at high doses as immunomodulatory and anti-inflammatory therapy, in the treatment of IEI ...
Francesca Conti, Mattia Moratti, Lucia Leonardi, Arianna Catelli, Elisa Bortolamedi, Emanuele Filice, Anna Fetta, Marianna Fabi, Elena Facchini, Maria Elena Cantarini, Angela Miniaci, Duccio Maria Cordelli, Marcello Lanari, Andrea Pession, Daniele Zama   +14 more
doaj   +1 more source

A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations [PDF]

, 2019
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. Exacerbations may involve increasing bulbar weakness and/or sudden respiratory failure, both of which can be critically disabling.
Ayguasanosa, J, Balasa, R, Bril, V, Camprubi, S, Chen, J, De Bleecker, Jan, Garcia, B, Griffin, R, Heckmann, JM, Henriquez, W, Karelis, G, Lagrange, E, Mondou, E, Nicolle, M, Stuchevskaya, T, Van Damme, P, Vilciu, C, Villa, A   +17 more
core   +2 more sources

Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris [PDF]

BMJ Case Reports, 2018
A novel administration strategy of immunoglobulin treatment is represented by injection of recombinant human hyaluronidase (rHUPH20) with subcutaneous immunoglobulins. The use of facilitated subcutaneous immunoglobulin treatment (fSCIG) for the treatment of autoimmune conditions is yet to be investigated.
Radin, Massimo, Roccatello, Dario, Baldovino, Simone, Sciascia, Savino   +3 more
openaire   +2 more sources